234P MRD evaluation of adjuvant aumolertinib in stage IB and IA2-3 EGFR-mutant NSCLC after complete surgical resection: A multicenter, single-arm, open-lable study
作者
C. Cheng,Z. Liu,Y. Liu,S. Ma,J. Zhang
出处
期刊:ESMO open [Elsevier BV] 日期:2026-03-17卷期号:11: 106542-106542
Although the Phase III ARTS study has reported outcomes of adjuvant aumolertinib in stage IIA–IIIB NSCLC, prospective evidence regarding its efficacy in completely resected stage I EGFR-mutant NSCLC remains limited. This multicenter, single-arm study aims to evaluate the efficacy and safety of adjuvant aumolertinib in stage IA2–3 and IB EGFR-mutant NSCLC after R0 resection.